Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01511640 · ClinicalTrials.gov registry record · Early Phase 1
Behavioral Effects of Pregabalin and Cannabis
A Early Phase 1 study of Cannabis Use Disorders, sponsored by Joshua A. Lile, Ph.D..
- Completed
- Registry status
- Early Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT01511640: Completed Early Phase 1 study of Cannabis Use Disorders, sponsored by Joshua A. Lile, Ph.D..
NCT01511640 is a Early Phase 1 study of Cannabis Use Disorders that has completed, run by Joshua A. Lile, Ph.D.. The registered enrollment target is 30 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (43% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01511640, a Early Phase 1 study of Cannabis Use Disorders, has completed, sponsored by Joshua A. Lile, Ph.D..
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Cannabis is the most commonly used illicit drug in the United States, and its use is associated with rates of development of abuse and dependence, treatment admission and relapse that are comparable to other illicit drugs. Currently there is no effective pharmacological treatment for cannabis-use disorders. The purpose of the present study is to evaluate the ability of pregabalin to reduce cannabis use thereby evaluating its effectiveness as a medication for cannabis-use disorders.
Primary Outcome
The reinforcing effects of cannabis were determined using a modified progressive ratio procedure in which subjects made 8 choices between puffs of each available cannabis dose and money (US$0.50). The numbered of self-administered puffs of smoked cannabis are measured for each cannabis concentration (0 and 5.9% THC) during active (300 and 450 mg) and placebo (0 mg and 0 mg) pregabalin maintenance.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Pregabalin
Study Locations (1)
Kentucky
- Laboratory of Human Behavioral Pharmacology - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2017-02-01 |
| Est. Completion | 2020-03-15 |
| Phase | Early Phase 1 |
What the finished NCT01511640 record still lists
NCT01511640 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (43% lower).
The record links to 1 condition, with Cannabis Use Disorders appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01511640 reports a single indexed study location in Kentucky.
Frequently Asked Questions
What is clinical trial NCT01511640 about?
NCT01511640 is a clinical study titled "Behavioral Effects of Pregabalin and Cannabis". Cannabis is the most commonly used illicit drug in the United States, and its use is associated with rates of development of abuse and dependence, treatment admission and relapse that are comparable to other illicit drugs. Currently there is no effective pharmacological treatment for cannabis-use di...
What is the current status of trial NCT01511640?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2017-02-01. Estimated completion is 2020-03-15.
What conditions does trial NCT01511640 study?
This clinical trial studies the following conditions: Cannabis Use Disorders.
What interventions are being tested in trial NCT01511640?
The interventions under investigation include: Placebo (DRUG), Pregabalin (DRUG).
Who is sponsoring clinical trial NCT01511640?
This trial is sponsored by Joshua A. Lile, Ph.D., which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01511640 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cannabis Use Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01511640's enrollment target sits among peer trials
30 807th of 2000 higher than 1,075 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI